SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer — Stella

Recruiting

Back to Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC) trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Serbia

The Institute for Pulmonary Diseases of Vojvodina, Kamenitz

Key details

Phase

Early testing / Safety & dosing

Sponsor

SN BioScience

Enrollment target

~55 participants

Started

March 2026

Primary completion

December 2028

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov